Royalty Pharma PLC

NAS:RPRXHealthcareNASDAQ:NBISTOXX:EDD24BP

$60.56−0.66%LiveIn session · ≈ AED 222.39 · Market cap $34.82B · Next earnings Wed 4 Nov

Ratio	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	Current · undated	YoY
Gross margin	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	—	—
Operating margin	75.2%	62.5%	13.7%	63.4%	57.1%	65.6%	65.6%	+0.0 pts
Net margin	45.9%	27.1%	1.9%	48.2%	37.9%	32.4%	55.7%	+23.3 pts
EBITDA margin	88.7%	62.5%	18.9%	80.2%	68.8%	68.8%	—	—
Return on equity	20.2%	10.7%	0.8%	17.4%	12.4%	11.9%	13.6%	+1.7 pts
Return on assets	6.1%	3.5%	0.3%	6.9%	4.7%	3.9%	6.7%	+2.8 pts
Return on capital employed	10.2%	8.2%	2.0%	9.2%	7.6%	8.2%	—	—
Debt / equity	1.2×	1.2×	1.3×	0.9×	1.1×	1.4×	0.9×	−33.3%
Debt / assets	36.3%	40.5%	42.3%	37.5%	41.8%	45.6%	—	—
Interest coverage	10.2×	8.6×	1.6×	8.0×	5.7×	5.1×	—	—
Current ratio	8.8×	16.8×	2.2×	7.9×	1.4×	1.0×	1.0×	+0.0%
Quick ratio	8.8×	16.8×	2.2×	7.9×	1.4×	1.0×	—	—
Cash ratio	3.3×	9.0×	1.5×	3.0×	0.7×	1.0×	1.0×	+0.0%
Asset turnover	0.1×	0.1×	0.1×	0.1×	0.1×	0.1×	—	—
Receivables turnover	54.2×	33.5×	61.1×	105.1×	84.0×	2.7×	—	—
Dividend payout	40.8%	46.0%	778.2%	31.6%	43.8%	49.1%	—	—

Margins, returns, leverage and liquidityUpdated 31 Dec 2025 ·

ⓘ

Current snapshot ratios have no reporting date and are shown separately from fiscal periods.